A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.
- Sponsor
- Institut Claudius Regaud
- Study ID
- NCT06022159
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Soft Tissue Sarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Hypofractionated Radiation Therapy — RADIATIONThe Hypofractionated Intensity-Modulated Radiation Therapy will be delivered in 5 fractions of 6 Gy each on the Planning Target Volume (PTV). The total dose of 30 Gy will be administered in approximately 1 week.
- Conservative treatment — PROCEDUREA wide en bloc resection is required (amputation is excluded) while ensuring the best functional preservation. The surgical procedure will take place about 1,5 to 2 months after the end of the radiation therapy.
Study Details
This is a phase II, multicenter, non-randomized study. The main objective is to evaluate the treatment with hypofractionated radiation therapy in neo-adjuvant situations on wound healing in a population of aged patients (≥ 70 years old) or ≥ 65 years of age defined as "fragile" and treated for soft tissue sarcoma. A maximum of 48 evaluable patients will be included in this study. The patients will receive an hypofractionated radiation therapy prior to conservative surgery. Each patient will be followed for up to 3 years after the end of complete treatment (radiotherapy + surgery).
Key Dates
- First listed
- Sep 1, 2023
- Start date
- Nov 28, 2023
- Status verified
- May 2026
- Primary completion
- Sep 30, 2026
- Completion
- May 31, 2029
Study Design
- Enrollment
- 48 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Radiation therapy followed by surgery
Primary Outcome Measure
The rate of patients free of major surgical complications as defined by O'Sullivan within 6 months of surgery. [ Time Frame: 6 month for each patient ]
Central Contacts
- Justine ATTAL KHALIFA05 31 15 54 38
Related Studies
- LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic OncologyPHASE4 · Enrolling By Invitation · Massachusetts General Hospital · Los Angeles, California
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationPHASE2 · Recruiting · Medical College of Wisconsin · Jacksonville, Florida
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue SarcomaPHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)PHASE1 · Recruiting · St. Jude Children's Research Hospital · Memphis, Tennessee